Etanercept as prophylactic psoriatic therapy before interferon-alpha and ribavirin treatment for active hepatitis C infection

S E Behnam; R Hindiyeh; D J Fife; E W Jeffes 3rd; J J Wu

doi:10.1111/j.1365-2230.2009.03476.x

Etanercept as prophylactic psoriatic therapy before interferon-alpha and ribavirin treatment for active hepatitis C infection

Clin Exp Dermatol. 2010 Jun;35(4):397-8. doi: 10.1111/j.1365-2230.2009.03476.x. Epub 2009 Jul 29.

Authors

S E Behnam¹, R Hindiyeh, D J Fife, E W Jeffes 3rd, J J Wu

Affiliation

¹ Department of Dermatology, University of California, Irvine, CA, USA.

PMID: 19663835
DOI: 10.1111/j.1365-2230.2009.03476.x

Abstract

Patients with psoriasis and chronic hepatitis C virus (HCV) infection are a therapeutic challenge. Systemic psoriasis treatment with methotrexate and acitretin can be hepatotoxic, and interferon (IFN)-alpha for treatment of HCV can worsen psoriasis. Etanercept can be successfully used in patients with psoriasis and HCV. To our knowledge, this is the first case report of etanercept used prophylactically to prevent a psoriatic flare in a patient with HCV treated with IFN-alpha and ribavirin.

Publication types

Case Reports

MeSH terms

Antiviral Agents / adverse effects
Antiviral Agents / therapeutic use
Drug Eruptions / etiology
Drug Eruptions / prevention & control
Drug Therapy, Combination
Etanercept
Hepatitis C, Chronic / drug therapy*
Humans
Immunoglobulin G / therapeutic use*
Interferon-alpha / adverse effects*
Interferon-alpha / therapeutic use
Male
Middle Aged
Psoriasis / chemically induced
Psoriasis / prevention & control*
Receptors, Tumor Necrosis Factor / therapeutic use*
Ribavirin / adverse effects*
Ribavirin / therapeutic use

Substances

Antiviral Agents
Immunoglobulin G
Interferon-alpha
Receptors, Tumor Necrosis Factor
Ribavirin
Etanercept